In a trial involving patients with type 2 diabetes and chronic kidney disease, Novo Nordisk’s Ozempic was found to reduce the risk of death. The diabetes drug lowered the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. The study suggests that treating 39 people with Ozempic over three years could prevent one death. Additionally, Ozempic reduced the risk of major heart complications by 18%, primarily driven by a lower rate of heart-related deaths. These results were presented at a meeting of the European Renal Association and published in the New England Journal of Medicine.
Source link
Ozempic cut risk of death in diabetes patients with chronic kidney disease
